Skip to main content

Table 4 Multivariate logistic regression analyses for SCR and post-vaccination SPR in participants with pre-vaccination HAI antibody titer < 40

From: Immunogenicity and safety of quadrivalent influenza vaccine among young and older adults in Tianjin, China: implication of immunosenescence as a risk factor

 

SCR

Post-vaccination SPR

aOR (95% CI)

P

aOR (95% CI)

P

H1N1 (N = 124)

 Age, years

0.955(0.92–0.992)

0.018

0.963(0.922–1.006)

0.091

 IV history

0.341(0.122–0.952)

0.04

0.362(0.118–1.114)

0.076

 Post-vaccination HAI

1.028(0.955–1.106)

0.461

1.165(1.062–1.277)

0.001

H3N2 (N = 139)

 Age, years

1.006(0.975–1.037)

0.722

1.023(0.987–1.06)

0.218

 IV history

0.537(0.235–1.228)

0.141

0.461(0.175–1.21)

0.116

 Post-vaccination HAI

0.933(0.878–0.992)

0.027

1.099(1.016–1.189)

0.018

B/Victoria (N = 133)

 Age, years

0.949(0.911–0.988)

0.011

0.947(0.901–0.996)

0.035

 IV history

0.461(0.164–1.291)

0.14

0.348(0.099–1.224)

0.1

 Post-vaccination HAI

1.044(0.967–1.127)

0.275

1.148(1.038–1.27)

0.007

B/Yamagata (N = 62)

 Age, years

0.764(0.629–0.929)

0.007

0.752(0.573–0.988)

0.041

 IV history

0.655(0.034–12.529)

0.779

0.015(0.000–11.705)

0.217

 Post-vaccination HAI

0.915(0.76–1.103)

0.352

1.255(0.931–1.691)

0.136

  1. Abbreviations: N Number of subjects in group, CI Confidence interval, aOR Adjusted odds ratio (adjusted for male sex, number of days after vaccine administration for blood sample collection, and common comorbid conditions including hypertension, hyperlipidemia, and diabetes mellitus); IV history influenza vaccination history in the previous year, HAI hemagglutination inhibition antibody titer